

David I Quinn Mbbs

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3070957/publications.pdf>

Version: 2024-02-01

361
papers

18,741
citations

17429

63
h-index

14197

128
g-index

367
all docs

367
docs citations

367
times ranked

23617
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017, 376, 1015-1026.	13.9	2,677
2	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet</i> , The, 2017, 389, 67-76.	6.3	1,728
3	Isolation of exosomes from whole blood by integrating acoustics and microfluidics. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 10584-10589.	3.3	633
4	HER kinase inhibition in patients with HER2- and HER3-mutant cancers. <i>Nature</i> , 2018, 554, 189-194.	13.7	572
5	Intermittent versus Continuous Androgen Deprivation in Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 368, 1314-1325.	13.9	482
6	Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3410-3415.	3.3	425
7	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 683-694.	13.9	394
8	Prolonged Fasting Reduces IGF-1/PKA to Promote Hematopoietic-Stem-Cell-Based Regeneration and Reverse Immunosuppression. <i>Cell Stem Cell</i> , 2014, 14, 810-823.	5.2	369
9	A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2003, 170, 1798-1803.	0.2	365
10	Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1652-1659.	0.8	332
11	Fasting and cancer treatment in humans: A case series report. <i>Aging</i> , 2009, 1, 988-1007.	1.4	305
12	Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 426-435.	5.1	272
13	Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1136-1142.	0.8	268
14	A Universal Standard for the Validation of Blood Pressure Measuring Devices. <i>Hypertension</i> , 2018, 71, 368-374.	1.3	257
15	Randomized Controlled Trial of Collaborative Care Management of Depression Among Low-Income Patients With Cancer. <i>Journal of Clinical Oncology</i> , 2008, 26, 4488-4496.	0.8	239
16	Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. <i>Nature Medicine</i> , 2010, 16, 324-328.	15.2	211
17	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with <i>FGFR3</i> Alterations. <i>Cancer Discovery</i> , 2018, 8, 812-821.	7.7	206
18	International Validation of a Preoperative Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. <i>Journal of Clinical Oncology</i> , 2002, 20, 3206-3212.	0.8	203

#	ARTICLE	IF	CITATIONS
19	Multicenter, Double-Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine/Cisplatin Plus Bevacizumab or Placebo in Patients With Malignant Mesothelioma. <i>Journal of Clinical Oncology</i> , 2012, 30, 2509-2515.	0.8	199
20	Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNT0328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2010, 16, 3028-3034.	3.2	187
21	Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. <i>Cancer Research</i> , 2003, 63, 4196-203.	0.4	185
22	The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC). , 2019, 7, 354.		182
23	Molecular markers of prostate cancer outcome. <i>European Journal of Cancer</i> , 2005, 41, 858-887.	1.3	173
24	Double-Blind, Randomized Trial of Docetaxel Plus Vandetanib Versus Docetaxel Plus Placebo in Platinum-Pretreated Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 507-512.	0.8	168
25	Oscillometric blood pressure: a review for clinicians. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 930-938.	2.3	159
26	Safety and feasibility of fasting in combination with platinum-based chemotherapy. <i>BMC Cancer</i> , 2016, 16, 360.	1.1	153
27	ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for Urothelial Carcinomaâ€”Neoadjuvant and Adjuvant Settings. <i>European Urology</i> , 2013, 63, 58-66.	0.9	151
28	Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2013, 14, 893-900.	5.1	139
29	Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis. <i>Journal of Urology</i> , 2015, 194, 378-385.	0.2	137
30	A universal standard for the validation of blood pressure measuring devices. <i>Journal of Hypertension</i> , 2018, 36, 472-478.	0.3	135
31	EphB4 Expression and Biological Significance in Prostate Cancer. <i>Cancer Research</i> , 2005, 65, 4623-4632.	0.4	129
32	Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2012, 37, 637-643.	0.7	125
33	Human immunodeficiency virus-related primary central nervous system lymphoma. <i>Cancer</i> , 2004, 100, 2627-2636.	2.0	123
34	Expression and Significance of Vascular Endothelial Growth Factor Receptor 2 in Bladder Cancer. <i>Journal of Urology</i> , 2006, 175, 1245-1252.	0.2	122
35	Formation and size distribution of self-assembled vesicles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, 2910-2915.	3.3	113
36	Baseline ¹⁸ F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1195-1201.	2.8	110

#	ARTICLE	IF	CITATIONS
37	Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317. <i>Journal of Clinical Oncology</i> , 2009, 27, 5788-5793.	0.8	108
38	A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. <i>Cancer</i> , 2014, 120, 2684-2693.	2.0	105
39	Validation Study of the Accuracy of a Postoperative Nomogram for Recurrence After Radical Prostatectomy for Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2002, 20, 951-956.	0.8	104
40	Expression of the zinc transporter ZnT4 is decreased in the progression from early prostate disease to invasive prostate cancer. <i>Oncogene</i> , 2003, 22, 6005-6012.	2.6	103
41	Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1797-1806.	0.8	102
42	Regorafenib for patients with previously untreated metastatic or unresectable renal-cell carcinoma: a single-group phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 1055-1062.	5.1	101
43	Factors influencing post-recurrence survival in bladder cancer following radical cystectomy. <i>BJU International</i> , 2012, 109, 846-854.	1.3	101
44	Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma. <i>European Journal of Cancer</i> , 2014, 50, 3145-3152.	1.3	99
45	Health-Related Quality-of-Life Analysis From KEYNOTE-045: A Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1579-1587.	0.8	97
46	Fabrication of conductive gelatin methacrylate-polyaniline hydrogels. <i>Acta Biomaterialia</i> , 2016, 33, 122-130.	4.1	90
47	Zinc-alpha2-glycoprotein Expression as a Predictor of Metastatic Prostate Cancer Following Radical Prostatectomy. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1420-1424.	3.0	89
48	Phase II Study of Aflibercept (VEGF-Trap) in Patients With Recurrent or Metastatic Urothelial Cancer, a California Cancer Consortium Trial. <i>Urology</i> , 2010, 76, 923-926.	0.5	89
49	Prognostic significance of preoperative factors in localized prostate carcinoma treated with radical prostatectomy. <i>Cancer</i> , 2003, 97, 1884-1893.	2.0	86
50	The AKT Inhibitor Perifosine in Biochemically Recurrent Prostate Cancer: A Phase II California/Pittsburgh Cancer Consortium Trial. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 433-437.	0.9	85
51	Differentiating mTOR inhibitors in renal cell carcinoma. <i>Cancer Treatment Reviews</i> , 2013, 39, 709-719.	3.4	85
52	Biophysics of Malarial Parasite Exit from Infected Erythrocytes. <i>PLoS ONE</i> , 2011, 6, e20869.	1.1	84
53	Pharmacokinetic and Pharmacodynamic Principles of Illicit Drug Use and Treatment of Illicit Drug Users. <i>Clinical Pharmacokinetics</i> , 1997, 33, 344-400.	1.6	83
54	Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel. <i>Journal of Clinical Oncology</i> , 2019, 37, 403-410.	0.8	83

#	ARTICLE	IF	CITATIONS
55	A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. <i>Anti-Cancer Drugs</i> , 2009, 20, 179-184.	0.7	82
56	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 517-526.	2.0	80
57	Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma. , 2016, 4, 81.		79
58	Appropriate Use Criteria for ¹⁸ F-FDG PET/CT in Restaging and Treatment Response Assessment of Malignant Disease. <i>Journal of Nuclear Medicine</i> , 2017, 58, 2026-2037.	2.8	78
59	Prognostic Significance of Pathologic Features in Localized Prostate Cancer Treated With Radical Prostatectomy: Implications for Staging Systems and Predictive Models. <i>Journal of Clinical Oncology</i> , 2001, 19, 3692-3705.	0.8	77
60	Adjuvant Vascular Endothelial Growth Factor–targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis. <i>European Urology</i> , 2018, 74, 611-620.	0.9	77
61	One-Year Follow-Up of Collaborative Depression Care for Low-Income, Predominantly Hispanic Patients With Cancer. <i>Psychiatric Services</i> , 2011, 62, 162-170.	1.1	76
62	Mediating International Crises. <i>Journal of Conflict Resolution</i> , 2003, 47, 279-301.	1.1	72
63	Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 1500-1509.	0.8	72
64	Radium-223 mechanism of action: implications for use in treatment combinations. <i>Nature Reviews Urology</i> , 2019, 16, 745-756.	1.9	71
65	Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). <i>Clinical Cancer Research</i> , 2017, 23, 7199-7208.	3.2	68
66	Differential growth and shape formation in plant organs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 12359-12364.	3.3	68
67	A Randomized Phase II Trial of the Matrix Metalloproteinase Inhibitor BMS-275291 in Hormone-Refractory Prostate Cancer Patients with Bone Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 1556-1563.	3.2	63
68	Experience with sorafenib and adverse event management. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 78, 24-32.	2.0	62
69	Microscopic and Gross Extravesical Extension in Pathological Staging of Bladder Cancer. <i>Journal of Urology</i> , 2004, 171, 640-645.	0.2	61
70	Phase I Study of Antisense Oligonucleotide Against Vascular Endothelial Growth Factor: Decrease in Plasma Vascular Endothelial Growth Factor With Potential Clinical Efficacy. <i>Journal of Clinical Oncology</i> , 2006, 24, 1712-1719.	0.8	60
71	Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1737-1743.	0.8	57
72	Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: A critical analysis of 1,994 patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e1-52.e9.	0.8	55

#	ARTICLE	IF	CITATIONS
73	Phase II Trial of Paclitaxel, Carboplatin and Gemcitabine in Patients With Locally Advanced Carcinoma of the Bladder. <i>Journal of Urology</i> , 2008, 180, 2384-2388.	0.2	54
74	Natural history of surgically treated bladder carcinoma with extravesical tumor extension. <i>Cancer</i> , 2003, 98, 955-961.	2.0	49
75	Improving treatment of depression among low-income patients with cancer: the design of the ADAPt-C study. <i>General Hospital Psychiatry</i> , 2007, 29, 223-231.	1.2	49
76	Serum Biomarkers of Bone Metabolism in Castration-Resistant Prostate Cancer Patients With Skeletal Metastases: Results From SWOG 0421. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju013.	3.0	49
77	Real-world outcomes of sipuleucel-L treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019, 125, 4172-4180.	2.0	49
78	Power Play: Mediation in Symmetric and Asymmetric International Crises. <i>International Interactions</i> , 2006, 32, 441-470.	0.6	47
79	Targeted β -Particle Therapy of Bone Metastases in Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2013, 38, 966-971.	0.7	46
80	Examining the management of muscle-invasive bladder cancer by medical oncologists in the United States. Funding source: The US Office of Management and Budget (0925-0046).. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 637-644.	0.8	46
81	Immunotherapy for castration-resistant prostate cancer: Progress and new paradigms. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 245-260.	0.8	45
82	Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial. <i>Targeted Oncology</i> , 2015, 10, 45-53.	1.7	45
83	Multiparametric liquid biopsy analysis in metastatic prostate cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	45
84	IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 355-355.	0.8	45
85	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	0.8	44
86	Recombinant interleukin-21 plus sorafenib for metastatic renal cell carcinoma: a phase 1/2 study. , 2014, 2, 2.		42
87	Up-Regulation of EphB4 in Mesothelioma and Its Biological Significance. <i>Clinical Cancer Research</i> , 2005, 11, 4305-4315.	3.2	41
88	A phase 2 multicenter study of tivantinib (ARQ 197) monotherapy in patients with relapsed or refractory germ cell tumors. <i>Investigational New Drugs</i> , 2013, 31, 1016-1022.	1.2	41
89	Circulating tumor cell telomerase activity as a prognostic marker for overall survival in <sc>SWOG</sc> 0421: A phase III metastatic castration resistant prostate cancer trial. <i>International Journal of Cancer</i> , 2015, 136, 1856-1862.	2.3	41
90	Comparative effectiveness of screening strategies for colorectal cancer. <i>Cancer</i> , 2017, 123, 1516-1527.	2.0	41

#	ARTICLE	IF	CITATIONS
91	Clinical Cancer Advances 2012: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2013, 31, 131-161.	0.8	40
92	Defective Interhemispheric Integration and Anomalous Language Lateralization in Children at Risk for Schizophrenia. <i>Journal of Nervous and Mental Disease</i> , 1986, 174, 418-427.	0.5	39
93	Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 526-537.	1.9	39
94	Phase I, Dose-Escalation Study of the Targeted Cytotoxic LHRH Analog AEZS-108 in Patients with Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 6277-6283.	3.2	39
95	Infigratinib in upper tract urothelial carcinoma versus urothelial carcinoma of the bladder and its association with comprehensive genomic profiling and/or cell-free DNA results. <i>Cancer</i> , 2020, 126, 2597-2606.	2.0	39
96	Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkin's Lymphoma or Multiple Myeloma. <i>Clinical Pharmacokinetics</i> , 2009, 48, 199-209.	1.6	37
97	Bevacizumab alone or in combination with TRC105 for patients with refractory metastatic renal cell cancer. <i>Cancer</i> , 2017, 123, 4566-4573.	2.0	37
98	A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer. <i>BJU International</i> , 2008, 102, 1601-1606.	1.3	35
99	One-Year Postapproval Clinical Experience with Radium-223 Dichloride in Patients with Metastatic Castrate-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2015, 30, 195-199.	0.7	34
100	Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. <i>Journal of Clinical Oncology</i> , 2018, 36, 1498-1504.	0.8	34
101	Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 61-68.	2.0	34
102	Discovery and preclinical evaluation of a novel class of small-molecule compounds in hormone-dependent and -independent cancer cell lines. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1105-1113.	1.9	33
103	Southwest oncology group phase II study of arsenic trioxide in patients with refractory germ cell malignancies. <i>Cancer</i> , 2006, 106, 2624-2629.	2.0	33
104	Cytokine Therapy: A Standard of Care for Metastatic Renal Cell Carcinoma?. <i>Clinical Genitourinary Cancer</i> , 2005, 4, 181-186.	0.9	32
105	Surgery and adjunctive chemotherapy for invasive bladder cancer. <i>Surgical Oncology</i> , 2002, 11, 55-63.	0.8	31
106	Paclitaxel, Ifosfamide, and Cisplatin Efficacy for First-Line Treatment of Patients With Intermediate- or Poor-Risk Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016, 34, 2478-2483.	0.8	31
107	Management Trends and Outcomes of Patients Undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder: Evolution of the University of Southern California Experience over 3,347 Cases. <i>Journal of Urology</i> , 2022, 207, 302-313.	0.2	31
108	Is Year of Radical Prostatectomy a Predictor of Outcome in Prostate Cancer?. <i>Journal of Urology</i> , 2004, 171, 692-696.	0.2	30

#	ARTICLE	IF	CITATIONS
109	Epidermal Growth Factor Receptor-targeted Therapy in Squamous Cell Carcinoma of the Penis: A Report of 3 Cases. <i>Urology</i> , 2014, 83, 159-166.	0.5	30
110	The mediating effects of effort upon the relationship between head injury severity and cognitive functioning. <i>Brain Injury</i> , 2003, 17, 377-387.	0.6	29
111	Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. <i>Maturitas</i> , 2011, 69, 296-303.	1.0	29
112	Oral Fenretinide in Biochemically Recurrent Prostate Cancer: A California Cancer Consortium Phase II Trial. <i>Clinical Genitourinary Cancer</i> , 2009, 7, 43-50.	0.9	28
113	Acute Renal Impairment after Immersion and Near-Drowning. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 382-386.	3.0	28
114	A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 689-694.	1.1	27
115	Crisis managers but not conflict resolvers: Mediating ethnic intrastate conflict in Africa. <i>Conflict Management and Peace Science</i> , 2013, 30, 387-406.	1.0	27
116	Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: a California Cancer Consortium trial. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 897-907.	1.1	27
117	Robotic salvage retroperitoneal and pelvic lymph node dissection for ¹⁸ F-PSMA-1007 recurrent prostate cancer: technique and initial series. <i>BJU International</i> , 2017, 120, 401-408.	1.3	27
118	Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. <i>Clinical Cancer Research</i> , 2018, 24, 4662-4671.	3.2	27
119	Bortezomib Plus Docetaxel in Advanced Non-small Cell Lung Cancer and Other Solid Tumors: A Phase I California Cancer Consortium Trial. <i>Journal of Thoracic Oncology</i> , 2006, 1, 126-134.	0.5	27
120	Angiogenesis-Targeted Therapies in Prostate Cancer. <i>Clinical Prostate Cancer</i> , 2004, 3, 165-173.	2.1	26
121	The Differential Expression of EphB2 and EphB4 Receptor Kinases in Normal Bladder and in Transitional Cell Carcinoma of the Bladder. <i>PLoS ONE</i> , 2014, 9, e105326.	1.1	26
122	Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project. <i>Annals of Oncology</i> , 2015, 26, 2392-2398.	0.6	25
123	Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5825-5837.	1.0	25
124	Prediction of Time to Hormonal Treatment Failure in Metastatic Castration-Sensitive Prostate Cancer with ¹⁸ F-FDG PET/CT. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1524-1530.	2.8	25
125	Current and recent clinical trials for perioperative systemic therapy for muscle invasive bladder cancer: a systematic review. <i>BMC Cancer</i> , 2014, 14, 966.	1.1	24
126	Controlled molecular self-assembly of complex three-dimensional structures in soft materials. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 70-74.	3.3	23

#	ARTICLE	IF	CITATIONS
127	Renal-Cell Cancer â€” Targeting an Immune Checkpoint or Multiple Kinases. <i>New England Journal of Medicine</i> , 2015, 373, 1872-1874.	13.9	22
128	A Phase II Trial of AEZS-108 in Castration- and Taxane-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 742-749.	0.9	21
129	Phase I Trial of SBRT to the Prostate Fossa After Prostatectomy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 50-60.	0.4	21
130	Abstract CT001: Neratinib in <i>HER2</i> or <i>HER3</i> mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study. <i>Cancer Research</i> , 2017, 77, CT001-CT001.	0.4	21
131	Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4504-4504.	0.8	21
132	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
133	Postchemotherapy residual masses in advanced seminoma: current management and outcomes. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 869-874.	1.1	20
134	Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 1391-1398.	3.2	20
135	SIU-ICUD recommendations on bladder cancer: systemic therapy for metastatic bladder cancer. <i>World Journal of Urology</i> , 2019, 37, 95-105.	1.2	19
136	Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients (pts) with previously treated advanced/metastatic urothelial carcinoma (mUC) with <i>FGFR3</i> alterations.. <i>Journal of Clinical Oncology</i> , 2016, 34, 4517-4517.	0.8	19
137	Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigatorâ€™s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 410-410.	0.8	19
138	Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 377-377.	0.8	19
139	A phase II study of the orally administered negative enantiomer of gossypol (AT-101), a BH3 mimetic, in patients with advanced adrenal cortical carcinoma. <i>Investigational New Drugs</i> , 2019, 37, 755-762.	1.2	18
140	Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1â€™3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3â€™altered Advanced/Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2020, 78, 916-924.	0.9	18
141	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). <i>Clinical Cancer Research</i> , 2021, 27, 1967-1973.	3.2	18
142	Intermittent (IAD) versus continuous androgen deprivation (CAD) in hormone sensitive metastatic prostate cancer (HSM1PC) patients (pts): Results of S9346 (INT-0162), an international phase III trial.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4-4.	0.8	18
143	Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 825-835.	1.1	17
144	Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.. <i>Journal of Clinical Oncology</i> , 2016, 34, LBA4500-LBA4500.	0.8	17

#	ARTICLE	IF	CITATIONS
145	Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC).. Journal of Clinical Oncology, 2017, 35, 4501-4501.	0.8	17
146	Review: Targeted therapy in renal cancer. Therapeutic Advances in Medical Oncology, 2009, 1, 183-205.	1.4	16
147	Tivozanib in the treatment of renal cell carcinoma. Biologics: Targets and Therapy, 2013, 7, 139.	3.0	16
148	KEYNOTE-564: A phase 3, randomized, double blind, trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4599-TPS4599.	0.8	16
149	Non-steroidal anti-inflammatory drugs. Medical Journal of Australia, 1995, 163, 155-158.	0.8	16
150	Far-Infrared/Submillimeter Astronomical Interferometry with Spaceborne Tether Formations. Astrophysics and Space Science, 2006, 302, 225-239.	0.5	15
151	Pain management, supportive and palliative care in patients with renal cell carcinoma. BJU International, 2007, 99, 1305-1312.	1.3	15
152	Conductive gelatin methacrylate-poly(aniline) hydrogel for cell encapsulation. Biomedical Physics and Engineering Express, 2018, 4, 015005.	0.6	15
153	Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics, 2020, 10, 3254-3262.	4.6	15
154	Association of Overall Survival with Glycolytic Activity of Castrate-Resistant Prostate Cancer Metastases. Radiology, 2015, 274, 624-625.	3.6	14
155	<i>AXIN2</i> expression predicts prostate cancer recurrence and regulates invasion and tumor growth. Prostate, 2016, 76, 597-608.	1.2	14
156	Safety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma. Investigational New Drugs, 2020, 38, 1807-1814.	1.2	14
157	Programmed Death 1 and Programmed Death Ligand 1 Inhibitors in Advanced and Recurrent Urothelial Carcinoma: Meta-analysis of Single-Agent Studies. Clinical Genitourinary Cancer, 2020, 18, 351-360.e3.	0.9	14
158	Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients (pts).. Journal of Clinical Oncology, 2016, 34, 4513-4513.	0.8	14
159	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). Journal of Clinical Oncology, 2022, 40, 3301-3309.	0.8	14
160	Oblimersen and β -interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium. Journal of Cancer Research and Clinical Oncology, 2007, 133, 705-711.	1.2	13
161	Cabazitaxel in prostate cancer: stretching a string. Lancet, The, 2010, 376, 1119-1120.	6.3	13
162	Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts. Cancers, 2019, 11, 577.	1.7	13

#	ARTICLE	IF	CITATIONS
163	Impact of FDG PET Imaging for Expanding Patient Eligibility and Measuring Treatment Response in a Genome-Driven Basket Trial of the Pan-HER Kinase Inhibitor, Neratinib. <i>Clinical Cancer Research</i> , 2019, 25, 7381-7387.	3.2	13
164	FDG PET/CT Demonstration of Pancreatic Metastasis From Prostate Cancer. <i>Clinical Nuclear Medicine</i> , 2011, 36, 961-962.	0.7	12
165	Immune Response to Sipuleucel-T in Prostate Cancer. <i>Cancers</i> , 2012, 4, 420-441.	1.7	12
166	Small Cell Bladder Cancer: Biology and Management. <i>Seminars in Oncology</i> , 2012, 39, 615-618.	0.8	12
167	What Medical, Urologic, and Radiation Oncologists Want from Molecular Imaging of Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2016, 57, 6S-12S.	2.8	12
168	Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium – an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879. <i>Investigational New Drugs</i> , 2021, 39, 812-820.	1.2	12
169	Molecular prognostic factors in bladder cancer. <i>BJU International</i> , 2005, 95, 739-742.	1.3	11
170	Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. <i>BJU International</i> , 2008, 102, 1086-1091.	1.3	11
171	Adjuvant chemotherapy for locally advanced urothelial carcinoma: an overview of the USC experience. <i>World Journal of Urology</i> , 2009, 27, 39-44.	1.2	11
172	Using Molecular Markers to Help Predict Who Will Fail after Radical Prostatectomy. <i>Prostate Cancer</i> , 2011, 2011, 1-15.	0.4	11
173	Phase I clinical trial of temsirolimus and vinorelbine in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1227-1234.	1.1	11
174	Baseline Glomerular Filtration Rate and Cisplatin- Induced Renal Toxicity in Urothelial Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 90-98.e1.	0.9	11
175	Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC). <i>Clinical Genitourinary Cancer</i> , 2019, 17, 241-247.e1.	0.9	11
176	Association between precystectomy epithelial tumor marker response to neoadjuvant chemotherapy and oncological outcomes in urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 1-11.	0.8	11
177	Use of Wearable Activity Tracker in Patients With Cancer Undergoing Chemotherapy: Toward Evaluating Risk of Unplanned Health Care Encounters. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 839-853.	1.0	11
178	Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. <i>Journal of Thoracic Oncology</i> , 2006, 1, 126-34.	0.5	11
179	Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). <i>Journal of Patient-Reported Outcomes</i> , 2018, 2, 27.	0.9	10
180	p53 nuclear accumulation as an early indicator of lethal prostate cancer. <i>British Journal of Cancer</i> , 2019, 121, 578-583.	2.9	10

#	ARTICLE	IF	CITATIONS
181	Protocol for a multi-centre, definitive randomised controlled trial of the effectiveness of Individual Placement and Support for employment support among people with alcohol and drug dependence. <i>Trials</i> , 2020, 21, 167.	0.7	10
182	Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2572-2572.	0.8	10
183	The Current and Future Application of Adjuvant Systemic Chemotherapy in Patients with Bladder Cancer Following Cystectomy. <i>Urologic Clinics of North America</i> , 2005, 32, 217-230.	0.8	9
184	A phase II trial of gefitinib and pegylated IFN α in previously treated renal cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2011, 16, 494-9.	1.0	9
185	Novel tyrosine kinase inhibitors for renal cell carcinoma. <i>Expert Review of Clinical Pharmacology</i> , 2014, 7, 67-73.	1.3	9
186	Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). <i>Clinical Genitourinary Cancer</i> , 2018, 16, e11-e21.	0.9	9
187	Radionuclide Hepatobiliary Scanning in Patients with AIDS-Related Sclerosing Cholangitis. <i>Clinical Nuclear Medicine</i> , 1993, 18, 417-422.	0.7	8
188	Characteristics of Early-Winter Caribou, &emgRangifer tarandus caribou&/emg, Feeding Sites in the Southern Purcell Mountains, British Columbia. <i>Canadian Field-Naturalist</i> , 2003, 117, 352.	0.0	8
189	First light adaptive optics systems and components for the Thirty Meter Telescope. <i>Proceedings of SPIE</i> , 2010, , .	0.8	8
190	Smoke-Free Multi-unit Housing Policies Show Promise in Reducing Secondhand Smoke Exposure Among Racially and Ethnically Diverse, Low-Income Seniors. <i>Journal of Immigrant and Minority Health</i> , 2017, 19, 1281-1289.	0.8	8
191	Training early childcare providers in evidence-based nutrition strategies can help improve nutrition policies and practices of early childcare centres serving racially and ethnically diverse children from low-income families. <i>Public Health Nutrition</i> , 2018, 21, 1212-1221.	1.1	8
192	Phase II California Cancer Consortium Trial of Gemcitabine-Eribulin Combination in Cisplatin-Ineligible Patients With Metastatic Urothelial Carcinoma: Final Report (NCI-9653). <i>Journal of Clinical Oncology</i> , 2019, 37, 2682-2688.	0.8	8
193	Habitat segregation and population structure of Caribbean sea anemones and associated crustaceans on coral reefs at Akumal Bay, Mexico. <i>Bulletin of Marine Science</i> , 2017, 93, 1025-1047.	0.4	8
194	Non-Invasive Profiling of Advanced Prostate Cancer via Multi-Parametric Liquid Biopsy and Radiomic Analysis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2571.	1.8	8
195	An Audit of Oestrogen Implant Hormone Replacement Therapy. <i>Australian and New Zealand Journal of Obstetrics and Gynaecology</i> , 1998, 38, 455-460.	0.4	7
196	Phase I Clinical Trial of Pegylated Liposomal Doxorubicin and Docetaxel in Patients With Advanced Solid Tumors. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 27-31.	0.6	7
197	Efficacy of Oxaliplatin Plus Pemetrexed in Chemotherapy Pretreated Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 416-422.	0.9	7
198	Cancer transcriptomic profiling from rapidly enriched circulating tumor cells. <i>International Journal of Cancer</i> , 2020, 146, 2845-2854.	2.3	7

#	ARTICLE	IF	CITATIONS
199	Overall survival and immune responses with sipuleucel-T and enzalutamide: STRIDE study.. Journal of Clinical Oncology, 2018, 36, 246-246.	0.8	7
200	Infigratinib in upper tract urothelial carcinoma vs urothelial carcinoma of the bladder and association with comprehensive genomic profiling/cell-free DNA results.. Journal of Clinical Oncology, 2019, 37, 4510-4510.	0.8	7
201	Epidermal Growth Factor Receptor, Excision-Repair Cross-Complementation Group 1 Protein, and Thymidylate Synthase Expression in Penile Cancer. Clinical Genitourinary Cancer, 2016, 14, 450-456.e1.	0.9	6
202	Sipuleucel-T product characterization across different disease states of prostate cancer.. Journal of Clinical Oncology, 2012, 30, 42-42.	0.8	6
203	Phase II trial of paclitaxel, ifosfamide, and cisplatin (TIP) for previously untreated patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).. Journal of Clinical Oncology, 2013, 31, 336-336.	0.8	6
204	The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five phase III trials.. Journal of Clinical Oncology, 2014, 32, 5002-5002.	0.8	6
205	Eribulin in advanced urothelial cancer (AUC) patients (pts): A California Cancer Consortium trialâ€”NCI/CTEP 7435.. Journal of Clinical Oncology, 2015, 33, 4504-4504.	0.8	6
206	Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs chemotherapy (chemo) for previously treated advanced urothelial cancer (UC) in KEYNOTE-045.. Journal of Clinical Oncology, 2017, 35, 4530-4530.	0.8	6
207	Overall survival (OS) of African-American (AA) and Caucasian (CAU) men who received sipuleucel-T for metastatic castration-resistant prostate cancer (mCRPC): Final PROCEED analysis.. Journal of Clinical Oncology, 2019, 37, 5035-5035.	0.8	6
208	Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment. Clinical Advances in Hematology and Oncology, 2017, 15, 543-551.	0.3	6
209	Albumin levels predict prognosis in advanced renal cell carcinoma treated with tyrosine kinase inhibitors: a systematic review and meta-analysis. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 12.e13-12.e22.	0.8	6
210	Treatment registry for outcomes in patients with castration-resistant prostate cancer (TRUMPET): a methodology for real-world evidence and research. Future Oncology, 2016, 12, 2689-2699.	1.1	5
211	Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clinical Genitourinary Cancer, 2017, 15, 635-641.	0.9	5
212	Low-dimensional dynamical characterization of human performance of cancer patients using motion data. Clinical Biomechanics, 2018, 56, 61-69.	0.5	5
213	NeuACT, a phase II, randomized, open-label trial of DN24-02: Updated analysis of HER2 expression, immune responses, product parameters, and safety in patients with surgically resected HER2+ urothelial cancer.. Journal of Clinical Oncology, 2014, 32, 296-296.	0.8	5
214	Circulating tumor cells (CTCs) in SWOG S1216: A phase 3 multicenter trial in metastatic hormone sensitive prostate cancer (mHSPC).. Journal of Clinical Oncology, 2016, 34, 11516-11516.	0.8	5
215	Single arm phase II study of docetaxel and lapatinib in metastatic urothelial cancer: USC trial 4B-10-4.. Journal of Clinical Oncology, 2016, 34, 424-424.	0.8	5
216	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. Journal of Clinical Oncology, 2018, 36, TPS712-TPS712.	0.8	5

#	ARTICLE	IF	CITATIONS
217	Infigratinib in Early-Line and Salvage Therapy for FGFR3-Altered Metastatic Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 35-42.	0.9	5
218	Show us a sign: the search for "game changing" prostate cancer biomarkers. <i>Lancet Oncology</i> , The, 2011, 12, 204-206.	5.1	4
219	Blood cells and their use in active immunotherapy of prostate cancer. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 528-533.	1.4	4
220	Warfarin Ridge. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1213.	1.2	4
221	Rapid changes in circulating tumor cells following anti-angiogenic therapy. <i>Convergent Science Physical Oncology</i> , 2015, 1, 015002.	2.6	4
222	Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e719-e727.	0.9	4
223	Influence of the facility caseload on the subsequent survival of men with localized prostate cancer undergoing radical prostatectomy. <i>Cancer</i> , 2019, 125, 3853-3863.	2.0	4
224	Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 486-493.	2.0	4
225	HER2 expression in patients (pts) with surgically resected urothelial cancer at high risk of recurrence screened for the phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2.. <i>Journal of Clinical Oncology</i> , 2013, 31, 292-292.	0.8	4
226	Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4541-4541.	0.8	4
227	A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential enzalutamide in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014, 32, e16071-e16071.	0.8	4
228	Multicenter sequential phase II study of flavopiridol plus oxaliplatin (Alvocidib) with or without 5-FU and leucovorin (LV) for patients (pts) with refractory germ cell tumors (GCT) including late relapse (LR).. <i>Journal of Clinical Oncology</i> , 2014, 32, 364-364.	0.8	4
229	Survival outcomes for African-American (AA) vs matched Caucasian (CAU) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (sip-T).. <i>Journal of Clinical Oncology</i> , 2017, 35, 192-192.	0.8	4
230	Enfortumab vedotin (EV) in patients (Pts) with metastatic urothelial carcinoma (mUC) with prior checkpoint inhibitor (CPI) failure: A prospective cohort of an ongoing phase 1 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 431-431.	0.8	4
231	P53 as a predictor of clinical outcome in localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 57-57.	0.8	4
232	A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression.. <i>Journal of Clinical Oncology</i> , 2019, 37, 517-517.	0.8	4
233	Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer. <i>Current Oncology Reports</i> , 2022, 24, 1287-1298.	1.8	4
234	Dissecting the rugby tackle: do shoulder pads contribute to cervical spine injuries?. <i>Medical Journal of Australia</i> , 1998, 169, 501-502.	0.8	3

#	ARTICLE	IF	CITATIONS
235	“The Wizard of Oz”: A Depiction of TBI-Related Neurobehavioral Syndromes. <i>Academic Psychiatry</i> , 2012, 36, 340.	0.4	3
236	FINITE DOMINATION AND NOVIKOV RINGS. ITERATIVE APPROACH. <i>Glasgow Mathematical Journal</i> , 2013, 55, 145-160.	0.2	3
237	Finite domination and Novikov rings: Laurent polynomial rings in two variables. <i>Journal of Algebra and Its Applications</i> , 2015, 14, 1550055.	0.3	3
238	Access to high-volume surgeons and the opportunity cost of performing radical prostatectomy by low-volume providers. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 459.e15-459.e24.	0.8	3
239	Mining Human Mobility to Quantify Performance Status. , 2017, , .		3
240	Abstract 5560: PD-1/PD-L1 blockade enhances MDM2 inhibitor activity in p53 wild-type cancers. <i>Cancer Research</i> , 2018, 78, 5560-5560.	0.4	3
241	Examining the management of muscle-invasive bladder cancer (MIBC) by medical oncologists (MO).. <i>Journal of Clinical Oncology</i> , 2012, 30, 298-298.	0.8	3
242	Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 274-274.	0.8	3
243	Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease. <i>Clinical Advances in Hematology and Oncology</i> , 2017, 15, 466-477.	0.3	3
244	Bladder cancer: from a therapeutic wilderness to so many options; a guide to practice in a changing landscape. <i>Annals of Oncology</i> , 2022, 33, 242-243.	0.6	3
245	Phase I clinical trial of weekly docetaxel and exisulind, a novel inducer of apoptosis. <i>Investigational New Drugs</i> , 2006, 24, 79-83.	1.2	2
246	Review: Cooperative group trials “ Southwest Oncology Group (SWOG) innovations in advanced prostate cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2009, 1, 69-77.	1.4	2
247	953 SIPULEUCEL-T IN AFRICAN AMERICANS: A SUBGROUP ANALYSIS OF THREE PHASE 3 TRIALS OF SIPULEUCEL-T IN METASTATIC CASTRATE RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2012, 187, .	0.2	2
248	Skate park injury: A new mechanism of sternoclavicular joint dislocation. <i>EMA - Emergency Medicine Australasia</i> , 2014, 26, 316-317.	0.5	2
249	Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study. <i>Cancer Chemotherapy and Pharmacology</i> , 2017, 79, 339-351.	1.1	2
250	Evaluating Changes in Immune Function and Bone Microenvironment During Radium-223 Treatment of Patients with Castration-Resistant Prostate Cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2020, 35, 485-489.	0.7	2
251	Immune response from STRIDE, a randomized, phase 2, open label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5040-5040.	0.8	2
252	Safety and efficacy of everolimus (E), bevacizumab (B), and docetaxel (D) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 5066-5066.	0.8	2

#	ARTICLE	IF	CITATIONS
253	A phase I/II, open-label, dose-finding study to evaluate safety, pharmacodynamics, and efficacy of pembrolizumab (MK-3475) in combination with vorinostat in patients with advanced renal or urothelial cell carcinoma.. Journal of Clinical Oncology, 2016, 34, TPS4581-TPS4581.	0.8	2
254	Adjuvant axitinib dose modification in renal cell carcinoma (RCC): Analysis of the ATLAS study.. Journal of Clinical Oncology, 2019, 37, 4573-4573.	0.8	2
255	Clinical outcomes in Caucasian (C), African American (AA) and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 186-186.	0.8	2
256	Towards the cloning of the calf prochymosin gene. Biochemical Society Transactions, 1984, 12, 487-488.	1.6	1
257	Urethral Cancer. , 2006, , 27-37.		1
258	Speeding dating for docetaxel and recent debutantes in castration-resistant prostate cancer: "plus or minus"™ may be a minus. Annals of Oncology, 2013, 24, 270-272.	0.6	1
259	Chromoplexy and hypoxic microenvironment drives prostate cancer. Lancet Oncology, The, 2014, 15, 1419-1421.	5.1	1
260	Sequencing therapy in advanced prostate cancer: focus on sipuleucel-T. Expert Review of Anticancer Therapy, 2014, 14, 51-61.	1.1	1
261	Oscillometric blood pressure. Blood Pressure Monitoring, 2014, 19, 255.	0.4	1
262	Durable Complete Remission From Castration-Resistant Prostate Cancer With Sipuleucel-T After Estrogen Withdrawal. Clinical Genitourinary Cancer, 2014, 12, e55-e58.	0.9	1
263	Relapsed and refractory germ cell tumors: Finessing the rough end of a beautiful story. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 341-342.	0.8	1
264	Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. JNCI Cancer Spectrum, 2020, 4, pkaa003.	1.4	1
265	Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature. Clinical Genitourinary Cancer, 2020, 18, e473-e477.	0.9	1
266	Abstract 2718: Fasting and cancer treatment: A case series. , 2010, , .		1
267	Abstract CT162: Pembrolizumab monotherapy for the adjuvant treatment of renal cell carcinoma post-nephrectomy: Randomized, double-blind, Phase III KEYNOTE-564 study. , 2019, , .		1
268	HPV status in relation to clinicopathologic variables in patients with penile cancer at Los Angeles County-USC Medical Center.. Journal of Clinical Oncology, 2012, 30, 329-329.	0.8	1
269	Changes in circulating tumor cells (CTC) and markers of inflammation after sipuleucel-T treatment.. Journal of Clinical Oncology, 2013, 31, 40-40.	0.8	1
270	International randomized, double-blind, placebo-controlled, phase 3 study of linsitinib (OSI-906, L) in patients (pts) with locally advanced or metastatic adrenocortical carcinoma (ACC).. Journal of Clinical Oncology, 2014, 32, 4507-4507.	0.8	1

#	ARTICLE	IF	CITATIONS
271	SWOG S0925: A randomized phase 2 study of androgen deprivation combined with cixutumumab versus androgen deprivation alone in patients with new metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2014, 32, 5006-5006.	0.8	1
272	Abiraterone plus prednisone alone or with dasatinib in chemotherapy-naïve metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, TPS5108-TPS5108.	0.8	1
273	Randomized phase 2 study of trebananib (AMG 386) with or without continued anti-vascular endothelial growth factor (VEGF) therapy in patients (pts) with renal cell carcinoma (RCC) who have progressed on bevacizumab, pazopanib, sorafenib, or sunitinib.. Journal of Clinical Oncology, 2016, 34, e16121-e16121.	0.8	1
274	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose Interleukin 2 in renal cell carcinoma patients (CTEP#7870).. Journal of Clinical Oncology, 2016, 34, 500-500.	0.8	1
275	Antigen spread (AgS) after sipuleucel-T (sip-T): A cross-trial comparison of 4 sip-T clinical trials of patients (pts) with prostate cancer (PC).. Journal of Clinical Oncology, 2017, 35, 143-143.	0.8	1
276	Impact of resistance exercise on metabolic syndrome (MetS) parameters in men receiving androgen deprivation therapy (ADT) for prostate cancer.. Journal of Clinical Oncology, 2017, 35, 223-223.	0.8	1
277	THE INCIDENCE ALGEBRA OF POSETS AND ACYCLIC CATEGORIES. Kyushu Journal of Mathematics, 2013, 67, 117-127.	0.2	1
278	ATLAS study: A randomized double-blind phase 3 study of adjuvant axitinib versus placebo in subjects at high risk of recurrent renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2014, 32, TPS4595-TPS4595.	0.8	1
279	Sipuleucel-T (sip-T)â€œinduced proliferative CD8+ T-cell responsesâ€œto immunizing and secondary antigens.. Journal of Clinical Oncology, 2016, 34, 165-165.	0.8	1
280	Comparative effectiveness of initiating colorectal cancer (CRC) screening (Scr) at age 45.. Journal of Clinical Oncology, 2017, 35, 531-531.	0.8	1
281	Randomized phase II trial of abiraterone +/- dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 167-167.	0.8	1
282	Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.. Journal of Clinical Oncology, 2017, 35, 5023-5023.	0.8	1
283	High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry.. Journal of Clinical Oncology, 2018, 36, 624-624.	0.8	1
284	Biomarkers of outcomes in a randomized phase II trial of first-line paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for intermediate- and poor-risk germ cell tumors (GCT).. Journal of Clinical Oncology, 2019, 37, 4563-4563.	0.8	1
285	The future in advanced prostate cancer: take your partners or is the last dance for me?. Reviews in Urology, 2004, 6 Suppl 10, S29-44.	0.9	1
286	A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2022, 20, 415-422.	0.9	1
287	Tinea of the skin, hair and nails. Medical Journal of Australia, 1996, 165, 350-351.	0.8	0
288	Creative approaches to staff development: global education in ITE in The Gambia. Education 3-13, 2007, 35, 117-131.	0.6	0

#	ARTICLE	IF	CITATIONS
289	Perioperative chemotherapy for urothelial cancer. <i>Cancer</i> , 2009, 115, 5139-5142.	2.0	0
290	RAPIDLY ALTERNATING, DOSE-DENSE CHEMOTHERAPY AND RETROPERITONEAL LYMPH NODE DISSECTION (RPLND): OUTCOMES IN PATIENTS WITH HIGH-RISK NON-SEMINOMATOUS GERM CELL TUMOR. <i>Journal of Urology</i> , 2009, 181, 198-198.	0.2	0
291	1983 FACTORS INFLUENCING POST-RECURRENCE SURVIVAL IN BLADDER CANCER PATIENTS FOLLOWING RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
292	1589 INFLUENCE OF SMOKING HISTORY ON BLADDER CANCER PATIENT OUTCOME FOLLOWING RADICAL CYSTECTOMY. <i>Journal of Urology</i> , 2011, 185, .	0.2	0
293	MP41-09 AXIN2 PREDICTS PROSTATE CANCER RECURRENCE AFTER RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
294	MP61-15 IMPACT OF GENDER ON POST-CYSTECTOMY BLADDER CANCER OUTCOMES: DIFFERENCES IN OBSERVATIONS BETWEEN MATCHED AND UNMATCHED CASE-CONTROL APPROACHES. <i>Journal of Urology</i> , 2014, 191, .	0.2	0
295	PD31-10 OUTCOMES FOLLOWING POST-CYSTECTOMY RECURRENCE OF BLADDER CANCER BASED ON METASTATIC SITE. <i>Journal of Urology</i> , 2015, 193, .	0.2	0
296	Trauma care and education. <i>Clinical Teacher</i> , 2015, 12, 291-291.	0.4	0
297	PD27-12 PRIMARY ANALYSIS OF IMVIGOR 210: ATEZOLIZUMAB IN PLATINUM-TREATED ADVANCED UROTHELIAL CARCINOMA. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
298	MP06-05 PRECYSTECTOMY EPITHELIAL TUMOR MARKER RESPONSE TO NEOADJUVANT CHEMOTHERAPY AND ITS EFFECT ON ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER. <i>Journal of Urology</i> , 2016, 195, .	0.2	0
299	Finite domination and Novikov rings. Laurent polynomial rings in several variables. <i>Journal of Pure and Applied Algebra</i> , 2016, 220, 2648-2682.	0.3	0
300	PD62-11 PREDICTIVE ROLE OF EPITHELIAL TUMOR MARKER LEVEL ELEVATION AT FOLLOW-UP FOR TUMOR RECURRENCE AND ONCOLOGICAL OUTCOMES IN UROTHELIAL BLADDER CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
301	Validating the total illness burden index for prostate cancer (TIBI-CaP) in men with castration-resistant prostate cancer: data from TRUMPET. <i>Future Oncology</i> , 2018, 14, 527-536.	1.1	0
302	EphrinB2 expression in prostate adenocarcinoma: Implications for targeted therapy. <i>Pathology Research and Practice</i> , 2020, 216, 152967.	1.0	0
303	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020, 126, 2935-2937.	2.0	0
304	Chapter 7 Systemic treatment: targeted therapies. , 2010, , .		0
305	Emerging Agents in Renal Cell Carcinoma. , 2012, , 285-301.		0
306	A combination herbal supplement for biochemically recurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 24-24.	0.8	0

#	ARTICLE	IF	CITATIONS
307	Neoadjuvant chemotherapy for muscle-invasive bladder cancer at the University of Southern California.. Journal of Clinical Oncology, 2012, 30, 301-301.	0.8	0
308	A phase I trial of AEZS-108 (AN-152) in castration- and taxane-resistant prostate cancer.. Journal of Clinical Oncology, 2012, 30, 60-60.	0.8	0
309	The University of Southern California penile cancer experience: Clinicopathologic characteristics of patients from 1991 to 2011.. Journal of Clinical Oncology, 2012, 30, 342-342.	0.8	0
310	Abstract LB-227: Targeted next-generation sequencing (NGS) of circulating tumor cells (CTCs) and matched primary tumors.. , 2013, , .		0
311	Identification of biologic and inflammatory markers for predicting clinical responses to sipuleucel-T in CRPC.. Journal of Clinical Oncology, 2014, 32, 134-134.	0.8	0
312	Clinical and biologic factors for immune response to sipuleucel-T (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 219-219.	0.8	0
313	Prostatectomy at high- versus low-volume centers: A decision analysis.. Journal of Clinical Oncology, 2014, 32, 175-175.	0.8	0
314	AXIN2 and prostate cancer recurrence after radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 145-145.	0.8	0
315	SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).. Journal of Clinical Oncology, 2014, 32, TPS5102-TPS5102.	0.8	0
316	Emerging Agents in Renal Cell Carcinoma. , 2015, , 385-402.		0
317	Dynamic changes in biomarkers for immune response to sipuleucel-t (SipT) for metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2015, 33, 181-181.	0.8	0
318	Effect of AXIN2 expression on prostate cancer recurrence and an invasive, tumorigenic phenotype.. Journal of Clinical Oncology, 2015, 33, 29-29.	0.8	0
319	Bevacizumab (Bev) alone or in combination with TRC105 for metastatic renal cell cancer (mRCC): A California Cancer Consortium clinical trial.. Journal of Clinical Oncology, 2015, 33, 4542-4542.	0.8	0
320	Colonoscopy versus less invasive approaches for colorectal cancer (CRC) screening (Scr): A strategic perspective.. Journal of Clinical Oncology, 2015, 33, 6523-6523.	0.8	0
321	Safety and pharmacokinetics (PK) of cabazitaxel (C) in patients (pts) with hepatic impairment (HI).. Journal of Clinical Oncology, 2015, 33, 2538-2538.	0.8	0
322	AXIN2 expression predicts prostate cancer recurrence and regulates invasion and tumor growth.. Journal of Clinical Oncology, 2015, 33, e16092-e16092.	0.8	0
323	Abstract 1587: Targeted sequencing of prostate cancer circulating tumor cells in comparison with matched cell free DNA and prostate tumors. , 2015, , .		0
324	Randomized phase I/II trial of two schedules of bortezomib and bevacizumab (BBmibmab) in metastatic renal cell cancer: USC trial 4K-05-1.. Journal of Clinical Oncology, 2016, 34, 574-574.	0.8	0

#	ARTICLE	IF	CITATIONS
325	Angiogenic markers during bevacizumab-based treatment in metastatic renal cell carcinoma (RCC).. Journal of Clinical Oncology, 2016, 34, 522-522.	0.8	0
326	Baseline GFR and cisplatin-induced renal toxicity in urothelial cancer patients.. Journal of Clinical Oncology, 2016, 34, 380-380.	0.8	0
327	The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.. Journal of Clinical Oncology, 2016, 34, 241-241.	0.8	0
328	Sipuleucel-T (sip-T) induced lytic CD8+ T cell responses to target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, e23116-e23116.	0.8	0
329	Immunogenicity of sipuleucel-T (Sip-T) in abiraterone (Abi)/enzalutamide (Enz) sensitive and resistant metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5077-5077.	0.8	0
330	FOBT compared to FIT in reducing colorectal cancer (CRC) incidence.. Journal of Clinical Oncology, 2016, 34, e18119-e18119.	0.8	0
331	The opportunity cost (OC) of low adherence with screening (scr) recommendations for colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, 1553-1553.	0.8	0
332	Validation of the association of RECIST 1.0 changes with survival in men with metastatic castration-resistant prostate cancer (mCRPC) treated on SWOG Study S0421.. Journal of Clinical Oncology, 2016, 34, 5079-5079.	0.8	0
333	Adjuvant chemotherapy for bladder cancer: A detailed characterization of factors precluding utilization.. Journal of Clinical Oncology, 2016, 34, e16001-e16001.	0.8	0
334	Targeted next generation sequencing (NGS) of matched primary tumor, metastasis, circulating tumor cells (CTCs), and cell-free DNA (cfDNA) in a patient with advanced prostate cancer (PC).. Journal of Clinical Oncology, 2016, 34, e23057-e23057.	0.8	0
335	The opportunity cost (OC) of performing radical prostatectomy (RP) by low volume (LV) providers (Prov).. Journal of Clinical Oncology, 2016, 34, 6509-6509.	0.8	0
336	Outcomes in neuroendocrine bladder cancer treated with radical cystectomy.. Journal of Clinical Oncology, 2016, 34, e16004-e16004.	0.8	0
337	Immunomodulation by HDAC inhibition: Results from a phase II study with entinostat and high-dose interleukin 2 in metastatic renal cell carcinoma patients (CTEP#7870).. Journal of Clinical Oncology, 2016, 34, 4560-4560.	0.8	0
338	Comparative effectiveness of CT colonography (CT-C) as a screening (Scr) tool for colorectal cancer (CRC).. Journal of Clinical Oncology, 2016, 34, e13049-e13049.	0.8	0
339	Abstract 3160: Circulating tumor cell enrichment and dielectric manipulation for ultra-pure cell recovery in advanced bladder cancer. , 2016, , .		0
340	Abstract CT015: Results from a phase I/II study with the HDAC inhibitor entinostat in combination with high-dose interleukin-2 in renal cell carcinoma patients (CTEP#7870). , 2016, , .		0
341	Eligibility criteria and endpoints in metastatic renal cell carcinoma trials.. Journal of Clinical Oncology, 2017, 35, 465-465.	0.8	0
342	Cytokine profile of sipuleucel-T (sip-T) in differentiating reactivation of latent immunity from de novo immune responses.. Journal of Clinical Oncology, 2017, 35, 163-163.	0.8	0

#	ARTICLE	IF	CITATIONS
343	P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).. Journal of Clinical Oncology, 2017, 35, TPS4592-TPS4592.	0.8	0
344	Adjuvant androgen deprivation (AD) +/- mitoxantrone + prednisone (MP) in patients with high-risk prostate cancer (PC) post radical prostatectomy (RP): Phase III intergroup trial S9921.. Journal of Clinical Oncology, 2017, 35, 5019-5019.	0.8	0
345	Sipuleucel-T (sip-T) to induce cytolytic T lymphocyte (CTL) activity against target antigens in men with hormone-sensitive and castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5046-5046.	0.8	0
346	Abstract 1717: Orthogonal identification of circulating tumor cells (CTCs) using single cell low pass whole-genome sequencing (WGS) and copy-number alteration (CNA) analysis. , 2017, , .		0
347	CT-based texture characterization of lymphadenopathy in urothelial carcinoma: Prediction of treatment response.. Journal of Clinical Oncology, 2018, 36, 514-514.	0.8	0
348	Novel method for rapid enrichment of high purity circulating tumor cells (CTCs) for prostate cancer (PCa) gene expression profiling.. Journal of Clinical Oncology, 2018, 36, 271-271.	0.8	0
349	Immune-related adverse events (irAE) in GU cancer patients receiving immune checkpoint inhibitors.. Journal of Clinical Oncology, 2018, 36, 422-422.	0.8	0
350	P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).. Journal of Clinical Oncology, 2018, 36, TPS574-TPS574.	0.8	0
351	Relationship between sipuleucel-T (sip-T) cytolytic T lymphocyte (CTL) activity and overall survival (OS) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2018, 36, 5027-5027.	0.8	0
352	Interpreting survival outcomes for African-American (AA) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with sipuleucel-T (SIP-T) with number needed to treat to benefit (NNTB).. Journal of Clinical Oncology, 2019, 37, 222-222.	0.8	0
353	EphB4-EphrinB2 receptor-ligand pair as a novel target in prostate cancer (PC).. Journal of Clinical Oncology, 2019, 37, 275-275.	0.8	0
354	Association of next generation sequencing characteristics of MIBC specimens with clinical outcomes: The USC experience.. Journal of Clinical Oncology, 2019, 37, 397-397.	0.8	0
355	Simple and rapid enrichment of circulating tumor cells (CTCs) for RNAseq in metastatic castrate resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, e16587-e16587.	0.8	0
356	PSA decline and objective response rates in White (W), Black (B), and Asian men with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, 5021-5021.	0.8	0
357	Abstract 3139: EphB4-EphrinB2 receptor-ligand are downstream effectors and novel targets of PTEN deficient prostate cancer. , 2019, , .		0
358	Editorial Comment. Journal of Urology, 2020, 203, 336-337.	0.2	0
359	Reply by Authors. Journal of Urology, 2022, 207, 313-313.	0.2	0
360	Impact of primary tumor location on efficacy and safety of pembrolizumab (pembro) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) enrolled in the phase 2 KEYNOTE-052 and phase 3 KEYNOTE-045 trials.. Journal of Clinical Oncology, 2022, 40, 516-516.	0.8	0

#	ARTICLE	IF	CITATIONS
361	Abstract 3736: SETD2 aberrancy enhanced the synergetic anti-tumor effects of DNA hypomethylating agents and PARP inhibitors in aggressive clear cell renal cell carcinoma. Cancer Research, 2022, 82, 3736-3736.	0.4	0